To evaluate if IL-17 was involved in this observed accumulation of CD11b+Ly6ClowLy6G+ cells and the increased rate of tumor development resulting from STAT1 deficiency, we examined the impact of anti-IL-17 treatment on MDSCs and neutrophil recruitment during CAC progression. The gene discussed is IL17A; the disease is neoplasm.